Akeso, Inc. (AKESF)
OTCMKTS
· Delayed Price · Currency is USD
7.80
0.00 (0.00%)
Dec 26, 2024, 4:00 PM EST
Akeso Employees
Akeso had 2,778 employees as of December 31, 2023. The number of employees increased by 437 or 18.67% compared to the previous year.
Employees
2,778
Change (1Y)
437
Growth (1Y)
18.67%
Revenue / Employee
$91,617
Profits / Employee
-$35,947
Market Cap
6.87B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 2,778 | 437 | 18.67% |
| Dec 31, 2022 | 2,341 | 476 | 25.52% |
| Dec 31, 2021 | 1,865 | 1,119 | 150.00% |
| Dec 31, 2020 | 746 | 356 | 91.28% |
| Dec 31, 2019 | 390 | - | - |
Akeso News
- 24 days ago - Akeso's Cadonilimab (PD-1/CTLA-4 Bispecific Antibody) Combination Therapy for PD-(L)1 Resistant NSCLC Showcased in Oral Presentation at 2024 Asian Conference on Lung Cancer - PRNewsWire
- 4 weeks ago - Akeso to Present at Citi 2024 Global Healthcare Conference and the 7th Annual Evercore HealthCONx Conference - PRNewsWire
- 4 weeks ago - Akeso Announced the Inclusion in China's National Reimbursement Drug List of Cadonilimab and Ivonescimab - PRNewsWire
- 5 weeks ago - Akeso's Penpulimab Combination Therapy for First-line Treatment of Hepatocellular Carcinoma Accepted by NMPA - PRNewsWire
- 5 weeks ago - Akeso Biopharma to Attend Jefferies London Healthcare Conference and Morgan Stanley 23rd Asia Pacific Summit - PRNewsWire
- 7 weeks ago - Akeso Published Mechanism of Action for CLDN18.2/CD47 Bispecific Antibody AK132 for the First Time at SITC Annual Meeting - PRNewsWire
- 2 months ago - Akeso Announces First Patient Enrollment in Phase 3 Trial of Ivonescimab Combination as First-Line Therapy for Biliary Tract Tumors, Compared to Durvalumab - PRNewsWire
- 2 months ago - Akeso Announces First Patient Enrollment in Phase 3 Trial of Ivonescimab Combined with Ligufalimab (CD47) for First-Line Treatment of Head and Neck Squamous Cell Carcinoma (HNSCC), Compared to Pembrolizumab - PRNewsWire